{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:16:10Z","timestamp":1792638970749,"version":"4.5.0"},"reference-count":89,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Population-based BRCA<\/jats:italic> testing can identify many more BRCA<\/jats:italic> carriers who will be missed by the current practice of BRCA<\/jats:italic> testing based on family history (FH) and clinical criteria. These carriers can benefit from screening and prevention, potentially preventing many more breast and ovarian cancers and deaths than the current practice.<\/jats:p><\/jats:sec>Objective<\/jats:title>To estimate the incremental lifetime health outcomes, costs, and cost-effectiveness associated with population-based BRCA<\/jats:italic> testing compared with FH-based testing in Canada.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>For this economic evaluation, a Markov model was developed to compare the lifetime costs and outcomes of BRCA1\/BRCA2<\/jats:italic> testing for all general population women aged 30 years compared with FH-based testing. BRCA<\/jats:italic> carriers are offered risk-reducing salpingo-oophorectomy to reduce their ovarian cancer risk and magnetic resonance imaging (MRI) and mammography screening, medical prevention, and risk-reducing mastectomy to reduce their breast cancer risk. The analyses were conducted from both payer and societal perspectives. This study was conducted from October 1, 2022, to February 20, 2024.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Outcomes of interest were ovarian cancer, breast cancer, additional heart disease deaths, and incremental cost-effectiveness ratio ICER per quality-adjusted life-year (QALY). One-way and probabilistic-sensitivity-analyses (PSA) were undertaken to explore the uncertainty.<\/jats:p><\/jats:sec>Results<\/jats:title>In the simulated cohort of 1\u202f000\u202f000 women aged 30 years in Canada, the base case ICERs of population-based BRCA<\/jats:italic> testing were CAD $32\u202f276 (US $23\u202f402.84) per QALY from the payer perspective or CAD $16\u202f416 (US $11\u202f903.00) per QALY from the societal perspective compared with FH-based testing, well below the established Canadian cost-effectiveness thresholds. Population testing remained cost-effective for ages 40 to 60 years but not at age 70 years. The results were robust for multiple scenarios, 1-way sensitivity, and PSA. More than 99% of simulations from payer and societal perspectives were cost-effective on PSA (5000 simulations) at the CAD $50\u202f000 (US $36\u202f254.25) per QALY willingness-to-pay threshold. Population-based BRCA<\/jats:italic> testing could potentially prevent an additional 2555 breast cancers and 485 ovarian cancers in the Canadian population, corresponding to averting 196 breast cancer deaths and 163 ovarian cancer deaths per 1\u202f000\u202f000 population.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this economic evaluation, population-based BRCA<\/jats:italic> testing was cost-effective compared with FH-based testing in Canada from payer and societal perspectives. These findings suggest that changing the genetic testing paradigm to population-based testing could prevent thousands of breast and ovarian cancers.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.32725","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T15:11:56Z","timestamp":1726153916000},"page":"e2432725","source":"Crossref","is-referenced-by-count":15,"title":["Economic Evaluation of Population-Based BRCA1<\/i> and BRCA2<\/i> Testing in Canada"],"prefix":"10.1001","volume":"7","author":[{"given":"Li","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, United Kingdom"},{"name":"Centre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, United Kingdom"},{"name":"Centre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin T.","family":"Fierheller","sequence":"additional","affiliation":[{"name":"Centre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesa","family":"Dawson","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Oxley","sequence":"additional","affiliation":[{"name":"Centre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom"},{"name":"Department of Gynaecological Oncology, Barts Health NHS Trust, Royal London Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Kalra","sequence":"additional","affiliation":[{"name":"Centre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom"},{"name":"Department of Gynaecological Oncology, Barts Health NHS Trust, Royal London Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Sia","sequence":"additional","affiliation":[{"name":"Centre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom"},{"name":"Department of Gynaecological Oncology, Barts Health NHS Trust, Royal London Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Feldman","sequence":"additional","affiliation":[{"name":"Prevention, Screening, Hereditary Cancer Program and Quality, Safety & Accreditation, BC Cancer Agency, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Peacock","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada"},{"name":"Canadian Centre for Applied Research in Cancer Control, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasmintan A.","family":"Schrader","sequence":"additional","affiliation":[{"name":"Hereditary Cancer Program, BC Cancer Agency, Vancouver, Canada"},{"name":"Department of Medical Genetics, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Legood","sequence":"additional","affiliation":[{"name":"Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, United Kingdom"},{"name":"Centre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice S.","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Manchanda","sequence":"additional","affiliation":[{"name":"Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, United Kingdom"},{"name":"Centre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom"},{"name":"Department of Gynaecological Oncology, Barts Health NHS Trust, Royal London Hospital, London, United Kingdom"},{"name":"MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, Faculty of Population Health Sciences, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"issue":"4","key":"zoi240986r1","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkaa029","article-title":"Penetrance of breast and ovarian cancer in women who carry a BRCA1\/2 mutation and do not use risk-reducing salpingo-oophorectomy: an updated meta-analysis.","volume":"4","author":"Chen","year":"2020","journal-title":"J Natl Cancer Inst Cancer Spectr"},{"issue":"23","key":"zoi240986r2","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"zoi240986r4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","article-title":"Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology.","volume":"19","author":"Daly","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"zoi240986r6","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.ejca.2007.04.023","article-title":"Genetic epidemiology of BRCA mutations\u2013family history detects less than 50% of the mutation carriers.","volume":"43","author":"M\u00f8ller","year":"2007","journal-title":"Eur J Cancer"},{"issue":"6","key":"zoi240986r7","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.18.01631","article-title":"Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle?","volume":"37","author":"Beitsch","year":"2019","journal-title":"J Clin Oncol"},{"issue":"17","key":"zoi240986r8","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.3390\/cancers13174344","article-title":"Implementation of multigene germline and parallel somatic genetic testing in epithelial ovarian cancer: SIGNPOST study.","volume":"13","author":"Chandrasekaran","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8","key":"zoi240986r9","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41591-020-0982-5","article-title":"Population genetic screening efficiently identifies carriers of autosomal dominant diseases.","volume":"26","author":"Grzymski","year":"2020","journal-title":"Nat Med"},{"issue":"34","key":"zoi240986r10","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1200\/JCO.2017.74.7899","article-title":"Genetic testing: what problem are we trying to solve?","volume":"35","author":"Hughes","year":"2017","journal-title":"J Clin Oncol"},{"issue":"34","key":"zoi240986r11","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1200\/JCO.2017.73.6314","article-title":"National estimates of genetic testing in women with a history of breast or ovarian cancer.","volume":"35","author":"Childers","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi240986r12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1136\/jmedgenet-2017-105195","article-title":"Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population.","volume":"55","author":"Manchanda","year":"2018","journal-title":"J Med Genet"},{"issue":"3","key":"zoi240986r13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10689-021-00270-0","article-title":"Patient ethnicity and cascade genetic testing: a descriptive study of a publicly funded hereditary cancer program.","volume":"21","author":"Braley","year":"2022","journal-title":"Fam Cancer"},{"issue":"1","key":"zoi240986r14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jama.2023.9526","article-title":"Germline genetic testing after cancer diagnosis.","volume":"330","author":"Kurian","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"zoi240986r16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.55324","article-title":"Cost-effectiveness of gene-specific prevention strategies for ovarian and breast cancer.","volume":"7","author":"Wei","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi240986r17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"zoi240986r18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","article-title":"Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.","volume":"16","author":"Cuzick","year":"2015","journal-title":"Lancet Oncol"},{"issue":"10218","key":"zoi240986r19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(19)32955-1","article-title":"Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.","volume":"395","author":"Cuzick","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"zoi240986r20","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","article-title":"Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.","volume":"22","author":"Rebbeck","year":"2004","journal-title":"J Clin Oncol"},{"key":"zoi240986r21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1146\/annurev-genom-083118-015253","article-title":"Population screening for inherited predisposition to breast and ovarian cancer.","volume":"21","author":"Manchanda","year":"2020","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"2","key":"zoi240986r22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/1471-0528.17283","article-title":"Population-based genetic testing for cancer susceptibility genes: quo vadis?","volume":"130","author":"Manchanda","year":"2023","journal-title":"BJOG"},{"issue":"1","key":"zoi240986r23","doi-asserted-by":"publisher","DOI":"10.1016\/j.gimo.2023.100824","article-title":"Carrier screening program for BRCA1\/BRCA2 pathogenic variants among Ashkenazi Jewish women in Israel: an observational study.","volume":"1","author":"Greenberg","year":"2023","journal-title":"Genet Med Open"},{"issue":"3","key":"zoi240986r24","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1470-2045(24)00087-1","article-title":"BRCA testing launched for people of Jewish ancestry in England.","volume":"25","author":"Venkatesan","year":"2024","journal-title":"Lancet Oncol"},{"issue":"7","key":"zoi240986r25","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.3390\/curroncol29070368","article-title":"Gynecologic cancer risk and genetics: informing an ideal model of gynecologic cancer prevention.","volume":"29","author":"Tindale","year":"2022","journal-title":"Curr Oncol"},{"issue":"2","key":"zoi240986r26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1001\/jama.296.2.185","article-title":"Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.","volume":"296","author":"Finch","year":"2006","journal-title":"JAMA"},{"issue":"1","key":"zoi240986r27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41416-019-0446-1","article-title":"International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.","volume":"121","author":"Metcalfe","year":"2019","journal-title":"Br J Cancer"},{"issue":"4","key":"zoi240986r28","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1097\/AOG.0b013e3182864350","article-title":"Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses\u2019 health study.","volume":"121","author":"Parker","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"3","key":"zoi240986r31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.12927\/hcpol.2017.25024","article-title":"Estimating the cost of cancer care in British Columbia and Ontario: a Canadian inter-provincial comparison.","volume":"12","author":"De Oliveira","year":"2017","journal-title":"Healthc Policy"},{"issue":"1","key":"zoi240986r33","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10549-009-0373-6","article-title":"Breast cancer-related preferences among women with and without BRCA mutations.","volume":"119","author":"Grann","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"zoi240986r34","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1136\/jmedgenet-2015-103077","article-title":"A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects.","volume":"52","author":"Jervis","year":"2015","journal-title":"J Med Genet"},{"issue":"1","key":"zoi240986r35","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.3747\/co.26.4068","article-title":"Selected medical interventions in women with a deleterious BRCA mutation: a population-based study in British Columbia.","volume":"26","author":"Hanley","year":"2019","journal-title":"Curr Oncol"},{"issue":"2","key":"zoi240986r36","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1258\/mi.2010.010023","article-title":"Compliance with estrogen hormone replacement therapy after oophorectomy: a prospective study.","volume":"16","author":"Read","year":"2010","journal-title":"Menopause Int"},{"issue":"8","key":"zoi240986r37","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3390\/cancers13081894","article-title":"The screen project: guided direct-to-consumer genetic testing for breast cancer susceptibility in Canada.","volume":"13","author":"Narod","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"13","key":"zoi240986r40","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.2005.04.3273","article-title":"Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five national surgical adjuvant breast and bowel project node-positive adjuvant breast cancer trials.","volume":"24","author":"Wapnir","year":"2006","journal-title":"J Clin Oncol"},{"issue":"15","key":"zoi240986r41","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1200\/JCO.2008.19.8424","article-title":"Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.","volume":"27","author":"Anderson","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi240986r43","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s41669-021-00257-8","article-title":"The healthcare cost burden in adults with high risk for cardiovascular disease.","volume":"5","author":"Tran","year":"2021","journal-title":"Pharmacoecon Open"},{"issue":"9880","key":"zoi240986r45","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/S0140-6736(13)60140-3","article-title":"Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.","volume":"381","author":"Cuzick","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"zoi240986r48","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/cge.12315","article-title":"A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes.","volume":"86","author":"Eggington","year":"2014","journal-title":"Clin Genet"},{"key":"zoi240986r49","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41525-018-0046-7","article-title":"Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices.","volume":"3","author":"Toland","year":"2018","journal-title":"NPJ Genom Med"},{"issue":"3","key":"zoi240986r50","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/GME.0000000000000990","article-title":"Age at natural menopause and its associated factors in Canada: cross-sectional analyses from the Canadian Longitudinal Study on Aging.","volume":"25","author":"Costanian","year":"2018","journal-title":"Menopause"},{"issue":"1","key":"zoi240986r51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/gme.0b013e31818888f7","article-title":"Increased cardiovascular mortality after early bilateral oophorectomy.","volume":"16","author":"Rivera","year":"2009","journal-title":"Menopause"},{"issue":"2","key":"zoi240986r53","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ygyno.2008.12.026","article-title":"Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment.","volume":"113","author":"Havrilesky","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"3","key":"zoi240986r55","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jval.2011.12.012","article-title":"Breast and prostate cancer productivity costs: a comparison of the human capital approach and the friction cost approach.","volume":"15","author":"Hanly","year":"2012","journal-title":"Value Health"},{"issue":"8","key":"zoi240986r57","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1158\/1055-9965.EPI-09-0171","article-title":"Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent.","volume":"18","author":"Evans","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"zoi240986r58","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12885-018-4242-8","article-title":"Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.","volume":"18","author":"Le Page","year":"2018","journal-title":"BMC Cancer"},{"issue":"26","key":"zoi240986r59","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1200\/JCO.2012.45.3571","article-title":"Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer.","volume":"31","author":"Huzarski","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi240986r60","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10549-009-0566-z","article-title":"Prognosis of BRCA-associated breast cancer: a summary of evidence.","volume":"119","author":"Bordeleau","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"zoi240986r61","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa070608","article-title":"Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.","volume":"357","author":"Rennert","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi240986r62","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/jnci\/djs494","article-title":"Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2.","volume":"105","author":"McLaughlin","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"zoi240986r63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1524-4733.2005.08101.x","article-title":"Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty.","volume":"8","author":"Briggs","year":"2005","journal-title":"Value Health"},{"issue":"5","key":"zoi240986r65","doi-asserted-by":"publisher","first-page":"578.e1","DOI":"10.1016\/j.ajog.2017.06.038","article-title":"Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry.","volume":"217","author":"Manchanda","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"zoi240986r66","first-page":"380","article-title":"Cost-effectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history-based testing.","volume":"107","author":"Manchanda","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"zoi240986r67","doi-asserted-by":"publisher","first-page":"431.e1","DOI":"10.1016\/j.ajog.2017.12.221","article-title":"Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women.","volume":"218","author":"Patel","year":"2018","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"zoi240986r68","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.3390\/cancers12071929","article-title":"Economic evaluation of population-based BRCA1\/BRCA2 mutation testing across multiple countries and health systems.","volume":"12","author":"Manchanda","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9","key":"zoi240986r69","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1038\/s41436-019-0457-6","article-title":"Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis.","volume":"21","author":"Zhang","year":"2019","journal-title":"Genet Med"},{"issue":"2","key":"zoi240986r70","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.56078","article-title":"Cost-effectiveness of population-based multigene testing for breast and ovarian cancer prevention.","volume":"7","author":"Guo","year":"2024","journal-title":"JAMA Netw Open"},{"key":"zoi240986r71","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102297","article-title":"Combined population genomic screening for three high-risk conditions in Australia: a modelling study.","volume":"66","author":"Lacaze","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"7","key":"zoi240986r72","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1093\/jnci\/djx265","article-title":"Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women.","volume":"110","author":"Manchanda","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"zoi240986r73","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.22874","article-title":"Cost-effectiveness of population-wide genomic screening for hereditary breast and ovarian cancer in the United States.","volume":"3","author":"Guzauskas","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi240986r74","first-page":"379","article-title":"Population testing for cancer predisposing BRCA1\/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.","volume":"107","author":"Manchanda","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"zoi240986r75","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/1471-0528.15905","article-title":"Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes.","volume":"127","author":"Manchanda","year":"2020","journal-title":"BJOG"},{"issue":"11","key":"zoi240986r76","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3390\/cancers10110424","article-title":"Population Based Testing for Primary Prevention: A Systematic Review.","volume":"10","author":"Manchanda","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"39","key":"zoi240986r77","doi-asserted-by":"publisher","first-page":"14205","DOI":"10.1073\/pnas.1415979111","article-title":"Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.","volume":"111","author":"Gabai-Kapara","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"zoi240986r79","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41576-022-00571-9","article-title":"Prioritizing the detection of rare pathogenic variants in population screening.","volume":"24","author":"Lacaze","year":"2023","journal-title":"Nat Rev Genet"},{"issue":"5","key":"zoi240986r80","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.3390\/cancers15051625","article-title":"Breast cancer risk and breast-cancer-specific mortality following risk-reducing salpingo-oophorectomy in BRCA carriers: a systematic review and meta-analysis.","volume":"15","author":"Gaba","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"zoi240986r81","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1471-0528.2011.03257.x","article-title":"Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis.","volume":"119","author":"Manchanda","year":"2012","journal-title":"BJOG"},{"issue":"7","key":"zoi240986r82","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/j.1471-0528.2011.02920.x","article-title":"Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.","volume":"118","author":"Manchanda","year":"2011","journal-title":"BJOG"},{"issue":"13","key":"zoi240986r83","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1245\/s10434-013-3108-1","article-title":"Operative risks associated with contralateral prophylactic mastectomy: a single institution experience.","volume":"20","author":"Miller","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"28","key":"zoi240986r84","doi-asserted-by":"publisher","first-page":"6890","DOI":"10.1200\/JCO.2005.02.626","article-title":"Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer.","volume":"23","author":"Madalinska","year":"2005","journal-title":"J Clin Oncol"},{"key":"zoi240986r85","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.bpobgyn.2020.01.006","article-title":"Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers.","volume":"65","author":"Gaba","year":"2020","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"4","key":"zoi240986r86","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.ajog.2023.03.045","article-title":"Quality of life after risk-reducing surgery for breast and ovarian cancer prevention: a systematic review and meta-analysis.","volume":"229","author":"Wei","year":"2023","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"zoi240986r87","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/1471-0528.16424","article-title":"Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study.","volume":"128","author":"Gaba","year":"2021","journal-title":"BJOG"},{"issue":"1","key":"zoi240986r88","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/pon.726","article-title":"Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy.","volume":"13","author":"Metcalfe","year":"2004","journal-title":"Psychooncology"},{"issue":"12","key":"zoi240986r89","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1111\/1471-0528.17253","article-title":"Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term secondary lifestyle behavioural outcomes.","volume":"129","author":"Burnell","year":"2022","journal-title":"BJOG"},{"key":"zoi240986r47","volume-title":"Familial Breast Cancer: Classification and Care of People at Risk of Familial Breast Cancer and Management of Breast Cancer and Related Risks in People With a Family History of Breast Cancer: NICE Clinical Guideline No. 164","author":"National Institute for Health and Care Excellence","year":"2016"},{"key":"zoi240986r64","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/978-981-19-7630-8_8","volume-title":"Cost-Effectiveness of Genetic Testing Strategies for Breast Cancer. Screening and Risk Reduction Strategies for Breast Cancer: Imaging Modality and Risk-Reduction Approaches","author":"Oxley","year":"2023"},{"key":"zoi240986r78","volume-title":"Key Health Inequalities in Canada: A National Portrait","author":"Public Health Agency of Canada","year":"2018"},{"key":"zoi240986r3","unstructured":"National Institute for Health and Care Excellence. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164). Accessed November 28, 2023. https:\/\/www.nice.org.uk\/guidance\/cg164"},{"key":"zoi240986r5","unstructured":"Hereditary Cancer Testing Eligibility Working Group. Hereditary cancer testing eligibility criteria: version 3. Accessed October 9, 2023. https:\/\/www.cancercareontario.ca\/en\/guidelines-advice\/types-of-cancer\/70161"},{"key":"zoi240986r15","unstructured":"Centers for Disease Control and Prevention. Tier 1 genomics applications and their importance to public health. Accessed October 10, 2023. https:\/\/archive.cdc.gov\/#\/details?url=https:\/\/www.cdc.gov\/genomics\/implementation\/toolkit\/tier1.htm"},{"key":"zoi240986r29","unstructured":"Ministry of Health. Medical services commission payment schedule 2021. Accessed April 13, 2023. https:\/\/www2.gov.bc.ca\/assets\/gov\/health\/practitioner-pro\/medical-services-plan\/msc-payment-schedule-may-2021.pdf"},{"key":"zoi240986r30","unstructured":"Canadian Institute for Health Information. Patient cost estimator. Accessed April 13, 2023. https:\/\/www.cihi.ca\/en\/patient-cost-estimator"},{"key":"zoi240986r32","unstructured":"National Institute for Health and Care Excellence. Advanced breast cancer: diagnosis and treatment. Accessed November 13, 2023. https:\/\/www.nice.org.uk\/guidance\/cg81"},{"key":"zoi240986r38","unstructured":"Sask Cancer Agency. Pan-Canadian oncology drug review. Accessed November 28, 2023. http:\/\/www.saskcancer.ca\/health-professionals-article\/pan-canadian-oncology-drug-review"},{"key":"zoi240986r39","unstructured":"Statistics Canada. Cancer in Canada: stage at diagnosis. Accessed November 28, 2023. https:\/\/www150.statcan.gc.ca\/n1\/pub\/82-003-x\/2018012\/article\/00003\/c-g\/c-g03-eng.htm"},{"key":"zoi240986r42","unstructured":"Nova Scotia Health system. Women & children\u2019s health program. 2023. Accessed January 15, 2023. https:\/\/www.nshealth.ca\/about-maternal-and-child-health-services"},{"key":"zoi240986r44","unstructured":"World Bank. Population, female. Accessed January 29, 2019. https:\/\/data.worldbank.org\/indicator\/SP.POP.TOTL.FE.IN?year_high_desc=true"},{"key":"zoi240986r46","unstructured":"Canadian Cancer Society. Screening for breast cancer. Accessed October 10, 2023. https:\/\/cancer.ca\/en\/cancer-information\/cancer-types\/breast\/screening"},{"key":"zoi240986r52","unstructured":"Canada\u2019s Drug and Health Technology Agency. Guidelines for the economic evaluation of health technologies: Canada. Accessed April 13, 2023. https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf"},{"key":"zoi240986r54","unstructured":"Canadian Cancer Statistics Advisory Committee; Canadian Cancer Society; Statistics Canada; Public Health Agency of Canada. Canadian cancer statistics 2021. Accessed April 13, 2023. https:\/\/cdn.cancer.ca\/-\/media\/files\/research\/cancer-statistics\/2021-statistics\/2021-pdf-en-final.pdf"},{"key":"zoi240986r56","unstructured":"Statistics Canada. Life expectancy and other elements of the complete life table, three-year estimates, Canada, all provinces except Prince Edward Island. 2022. Accessed November 13, 2023. https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1310011401"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2823637\/sun_2024_oi_240986_1725563653.77877.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T15:12:14Z","timestamp":1726153934000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2823637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":89,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.32725","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]}}}